Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Acute Myocardial Infarction Quality Assurance Project

Conditions:   Myocardial Infarction;   Death;   Heart Failure
Interventions:   Other: Quality Assurance Implementation;   Other: Standard of Care
Sponsor:   Dr. Derek Exner
Recruiting - verified March 2015

Patent Foramen Ovale and the Risk of Postoperative Delirium Following Elective Hip and Knee Arthroplasty Surgeries

Conditions:   Foramen Ovale, Patent;   Delirium;   Arthroplasty, Replacement, Hip;   Arthroplasty, Replacement, Knee
Intervention:   Other: TTE Bubble Study
Sponsor:   Lawson Health Research Institute
Recruiting - verified March 2015

Cardiovascular, Renal and Metabolic Profile in Patients With Acute Myocardial Infarction (REN-ACS)

Conditions:   Hypertension, Renovascular;   Renal Artery Stenosis;   Myocardial Infarction
Interventions:   Procedure: renal artery angiography;   Procedure: coronarography;   Procedure: coronary angioplasty;   Procedure: pulse wave velocity measurement;   Procedure: body composition monitoring
Sponsor:   Grigore T. Popa University of Medicine and Pharmacy
Recruiting - verified March 2015

SONOlysis in Prevention of Brain InfaRctions During Internal Carotid Endarterectomy

Condition:   Internal Carotid Artery Stenosis
Intervention:   Device: sonolysis
Sponsors:   University Hospital Ostrava;   Military University Hospital, Prague;   Vitkovice Hospital, Ostrava;   Masaryk Hospital, Usti nad Labem;   České Budějovice Hospital;   University Hospital Hradec Kralove;   University Hospital Plzen, Plzen;   County Hospital Liberec, Liberec
Not yet recruiting - verified March 2015

MagicTouch Sirolimus Drug Coated Balloon Catheter for the Treatment of Coronary Lesions

Condition:   Coronary Artery Disease
Intervention:   Device: MAGIC-TOUCH Drug-eluting Balloon
Sponsor:   Scitech Produtos Medicos Ltda
Not yet recruiting - verified March 2015

The Bicuspid Aortic Stenosis Following Transcatheter Aortic Valve Replacement Registry

Conditions:   Aortic Valve Stenosis;   Cardiovascular Diseases;   Heart Valve Diseases;   Bicuspid
Intervention:   Procedure: transcatheter aortic valve replacement
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Not yet recruiting - verified March 2015

Ciclosporin to Reduce Reperfusion Injury in Primary PCI

Condition:   Myocardial Reperfusion Injury
Interventions:   Drug: Ciclosporin;   Drug: Saline
Sponsors:   Newcastle-upon-Tyne Hospitals NHS Trust;   National Institute for Health Research Newcastle Biomedical Research Centre;   Newcastle University
Not yet recruiting - verified March 2015

Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)

Condition:   Hypertension
Interventions:   Device: Renal Denervation (Vessix);   Device: Renal Angiography
Sponsor:   Boston Scientific Corporation
Recruiting - verified March 2015

Study Comparing the MiStent SES Versus the XIENCE EES Stent

Condition:   Coronary Stenosis
Interventions:   Device: MiStent;   Device: XIENCE EES
Sponsors:   ECRI bv;   Micell Technologies;   Stentys
Not yet recruiting - verified February 2015

P3AMI Antiplatelet Trial

Condition:   Heart Attack
Interventions:   Drug: Prasugrel;   Drug: Clopidogrel;   Drug: ticagrelor
Sponsor:   The Royal Wolverhampton Hospitals NHS Trust
Recruiting - verified March 2015

Effect of an Atlantic Diet on Anthropometric Indices and Serum Lipid Profile

Condition:   Cardiovascular Disease
Intervention:   Behavioral: Diet
Sponsor:   Hospital Clinico Universitario de Santiago
Recruiting - verified March 2015

A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent AF

Condition:   Atrial Fibrillation
Interventions:   Device: single ablation (CryoBalloonAblation (CBA);   Drug: sequential drug adjustment (propafenone, sotalol or flecainide)
Sponsor:   University Hospital, Ghent
Not yet recruiting - verified March 2015

Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease

Condition:   Coronary Artery Disease
Interventions:   Procedure: Computed tomography angiography (cardiac CT);   Procedure: Invasive coronary angiography (ICA)
Sponsor:   Charite University, Berlin, Germany
Not yet recruiting - verified March 2015

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Conditions:   HIV Infections;   Cardiovascular Diseases
Interventions:   Drug: Pitavastatin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
Recruiting - verified March 2015

Endothelial Function-guided Therapy Compared to Usual Care in Patients With NOCAD

Condition:   Coronary Atherosclerosis
Intervention:  
Sponsor:   Itamar-Medical, Israel
Not yet recruiting - verified March 2015

RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Not yet recruiting - verified March 2015

Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers

Conditions:   Myocardial Infarction;   Inflammation;   Acute Coronary Syndrome (ACS);   Reperfusion Injury
Interventions:   Biological: Salmonella typhi vaccine (Typhim Vi®);   Drug: Oxygen (Oxymask®);   Drug: Atorvastatin
Sponsors:   Karolinska Institutet;   University Hospital, Linkoeping
Recruiting - verified March 2015

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified March 2015

Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography

Conditions:   Acute Kidney Injury;   Renal Insufficiency;   Kidney Diseases
Intervention:  
Sponsors:   HealthSpan Dx;   University of North Carolina, Chapel Hill
Recruiting - verified March 2015

Retrospective Multicenter Study to Determine 4-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-05 Study

Condition:   Cardiac Transplantation
Intervention:  
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2015

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Conditions:   Stroke;   Secondary Prevention
Interventions:   Drug: optional ASA as comedication;   Drug: placebo to ASA;   Drug: placebo to optional ASA as comedication;   Drug: placebo to dabigatran etexilate;   Drug: ASA 100 mg;   Drug: dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified March 2015

Prospective Evaluation of MyocaRdial PerFUSion ComputEd Tomography Trial

Condition:   Coronary Disease
Interventions:   Device: computed tomography perfusion guided treatment;   Device: Fractional flow reserve guided treatment
Sponsor:   Young-Hak Kim, MD, PhD
Recruiting - verified March 2015

Canadian SCAD Study

Condition:   Spontaneous Coronary Artery Dissection
Intervention:  
Sponsors:   Cardiology Research UBC;   Canadian Institutes of Health Research  (CIHR)
Recruiting - verified March 2015

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: Dabigatran Etexilate 110mg;   Drug: Warfarin 3mg;   Drug: Aspirin;   Drug: Dabigatran Etexilate 150mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 5mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 1mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified March 2015

Heartstrong Pilot Program

Condition:   Acute Myocardial Infarction
Interventions:   Behavioral: Social Influence;   Behavioral: Electronic Pill Bottles;   Behavioral: Financial Incentives
Sponsor:   University of Pennsylvania
Recruiting - verified April 2014

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Condition:   Acute Myocardial Infarction
Interventions:   Biological: CSL112;   Biological: Placebo
Sponsor:   CSL Behring
Recruiting - verified March 2015

DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury

Condition:   Coronary Artery Disease
Interventions:   Drug: Ticagrelor;   Drug: Placebo
Sponsors:   University of Edinburgh;   AstraZeneca
Recruiting - verified March 2015

Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Treatment 3 months DAPT;   Drug: Treatment 12 months DAPT
Sponsor:   Diagram B.V.
Recruiting - verified March 2015

Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.

Conditions:   Stable Angina;   Silent Myocardial Ischemia;   Acute Coronary Syndrome
Interventions:   Procedure: Percutaneous Coronary Intervention (PCI) with short DAPT duration with Synergy II stent;   Procedure: Percutaneous Coronary Intervention (PCI) with short DAPT duration with Omega stent;   Procedure: Percutaneous Coronary Intervention (PCI) with short DAPT duration with Rebel stent
Sponsor:   Ceric Sàrl
Recruiting - verified December 2014

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Conditions:   Pulmonary Embolism;   Thromboembolism;   Thrombosis;   Venous Thrombosis;   Venous Thromboembolism
Interventions:   Drug: BAY 59-7939;   Drug: BAY 59-7939;   Drug: ASA
Sponsor:   Bayer
Recruiting - verified March 2015

Evaluation of a Non-Invasive Electrocardiogram-Assisted Blood Pressure Monitor

Conditions:   Hypertension;   Atrial Fibrillation;   Obesity;   Heart Failure;   Atherosclerosis
Intervention:  
Sponsor:   Health Parametrics Inc.
Active, not recruiting - verified January 2014

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Condition:   Atrial Fibrillation
Interventions:   Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
Sponsors:   Pfizer;   Bristol-Myers Squibb
Recruiting - verified March 2015

Chronic Obstructive Pulmonary Disease Biomarker Study

Condition:   Chronic Obstructive Pulmonary Disease
Intervention:  
Sponsors:   University of British Columbia;   Genome British Columbia;   Centres of Excellence for Commercialization and Research - PROOF;   Canadian Institutes of Health Research  (CIHR);   Genome Quebec;   Providence Health & Services;   St. Paul's Hospital, Canada
Recruiting - verified March 2015

The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)

Condition:   Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction.
Intervention:   Biological: Allogeneic hMSCs
Sponsors:   Joshua M Hare;   The EMMES Corporation
Active, not recruiting - verified March 2015

Registry for Estimation of Warfarin and Rivaroxaban in Atrial Fibrillation Patients With Coronary Stent Implantation

Conditions:   Coronary Artery Disease;   Atrial Fibrillation;   Stroke;   Fetal Blood Loss
Intervention:   Drug: Warfarin or Rivaroxaban
Sponsors:   Fujita Health University;   Bayer Yakuhin, Ltd.
Recruiting - verified March 2015

Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD

Condition:   Coronary Artery Dissection, Spontaneous
Interventions:   Drug: ramipril;   Drug: rosuvastatin;   Drug: placebo
Sponsor:   Cardiology Research UBC
Recruiting - verified July 2014

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Ticagrelor 90 mg;   Drug: Ticagrelor placebo
Sponsor:   AstraZeneca
Recruiting - verified March 2015

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified March 2015

STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial

Conditions:   Anterior Acute Myocardial Infarction;   Left Ventricular Systolic Dysfunction
Intervention:   Drug: G-CSF administration
Sponsors:   Heart Care Foundation;   A. Manzoni Hospital;   Centro Cardiologico Monzino
Recruiting - verified March 2015

Specimen Procurement& Data Collection Protocol for The Rapid Evaluation of Possible Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Intervention:   Other: OBSERVATIONAL REGISTRY
Sponsor:   Henry Ford Health System
Recruiting - verified March 2015

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified March 2015

Prevalence of Morbidity in Newly Diagnosed type2 Diabetes in Adults

Conditions:   Type2 Diabetes Mellitus;   Complications
Intervention:   Other: no specific treatment
Sponsors:   University of Algiers;   National Institute of public Health, Algeria;   Ain-Taya's hospital, Algiers;   Parnet's teaching Hospital, Algiers;   Mustapha Pacha's teaching hospital, Algiers;   Birtraria's teaching hospital, Algiers;   Bab el Oued's teaching hospital, Algiers
Completed - verified March 2015

Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Prasugrel;   Drug: Clopidogrel
Sponsor:   Klinikum der Universitaet Muenchen
Recruiting - verified March 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Acenocoumarol
Sponsor:   Bayer
Recruiting - verified March 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified March 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Phenprocoumon
Sponsor:   Bayer
Recruiting - verified March 2015

The Effect of Tranexamic Acid on Transfusion Rates in Intertrochanteric Hip Fractures

Conditions:   Hip Fracture;   Blood Loss
Intervention:   Drug: Tranexamic Acid
Sponsor:   Hospital for Special Surgery, New York
Suspended - verified March 2015

High-sensitivity Troponin in Cardiac Surgery

Conditions:   Heart; Dysfunction Postoperative, Cardiac Surgery;   Myocardial Infarction;   Myocardial Injury
Intervention:   Other: serum concentration changes cardiac biomarkers
Sponsors:   Onze Lieve Vrouw  Hospital;   Roche Farma, S.A
Completed - verified March 2015

Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair

Condition:   Surgical Procedures
Interventions:   Drug: GSK1278863;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified March 2015

Multiple Daily Doses of Aspirin to Overcome Hyporesponsiveness Post Cardiac Bypass Surgery (ASACABG)- Part B

Condition:   Postoperative Dysfunction Following Cardiac Surgery
Interventions:   Drug: Aspirin;   Drug: Aspirin;   Drug: Aspirin
Sponsor:   Hamilton Health Sciences Corporation
Completed - verified March 2015

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified March 2015

Omega-3 Supplementation for Tetraplegics With Poor Cholesterol Levels

Conditions:   Spinal Cord Injury;   Tetraplegia;   Quadraplegia;   Low HDL-c;   High LDL-c
Intervention:   Dietary Supplement: Omega-3 supplements
Sponsors:   University of Manitoba;   The Association of Rehabilitation Medicine in Manitoba
Recruiting - verified March 2015

Application for Self-Monitoring of Cardiovascular Risk

Condition:   Coronary Artery Disease Which Requires Percutaneous Coronary Intervention(Balloon and/or Stent Treatment).
Intervention:   Device: Self Monitoring Software Application
Sponsor:   Mayo Clinic
Active, not recruiting - verified March 2015

Partners and Alerts: A Study of Social Forces in Medication Adherence

Condition:   Acute Myocardial Infarction (AMI)
Interventions:   Behavioral: Electronic Pill Bottle tracking;   Behavioral: Adherence Messaging;   Behavioral: Social Influence;   Behavioral: Medication schedule alarms
Sponsor:   University of Pennsylvania
Recruiting - verified June 2013

High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome

Conditions:   Acute Coronary Syndrome;   Myocardial Infarction
Intervention:   Device: High-sensitivity troponin I assay
Sponsors:   University of Edinburgh;   NHS Lothian;   NHS Greater Glasgow and Clyde;   Abbott Diagnostics Division
Recruiting - verified March 2015

Angiogenesis and Fibrosis in Myocardial Infarction

Conditions:   Myocardial Infarction;   Fibrosis;   Neovascularization, Pathologic
Interventions:   Procedure: Cardiac MRI scan;   Radiation: CT-PET scan;   Radiation: CT-coronary angiogram
Sponsor:   University of Edinburgh
Recruiting - verified March 2015

Atrial Fibrillation (AF) and Physical Exercise

Condition:   Atrial Fibrillation
Intervention:   Other: Physical Exercise
Sponsors:   Hvidovre University Hospital;   Sygekassernes Helsefond;   Eva og Henry Frænkels Mindefond;   Sanofi;   Thorkild Steenbecks Legat;   Toyota-Fonden;   Snedkermester Sophus Jacobsen and hustru Astrid Jacobsens Foundation
Active, not recruiting - verified March 2015

Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)

Condition:   Patients With Principal or Secondary Diagnosis Code of Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410 (Except When 5th Digit Was 2)
Intervention:   Behavioral: Electronic Pill Bottle, Incentives, Social Influence
Sponsor:   University of Pennsylvania
Active, not recruiting - verified April 2013

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

Conditions:   Pancreatic Cancer;   Pancreatic Carcinoma Non-resectable;   Locally Advanced Malignant Neoplasm
Interventions:   Drug: FOLFIRINOX;   Biological: Algenpantucel-L Immunotherapy;   Radiation: 5-FU Chemoradiation;   Drug: Gemcitabine;   Drug: Capecitabine;   Drug: Nab-Paclitaxel
Sponsor:   NewLink Genetics Corporation
Recruiting - verified March 2015

An Efficacy and Outcome Study of Supplemental Oxygen Treatment in Patients With Suspected Myocardial Infarction

Conditions:   Acute Coronary Syndrome;   Non-ST Elevation (NSTEMI) Myocardial Infarction;   Acute ST Segment Elevation Myocardial Infarction;   Angina, Unstable
Intervention:   Drug: Oxygen
Sponsors:   Karolinska Institutet;   Swedish Heart Lung Foundation;   Swedish Foundation for Strategic Research;   The Swedish Research Council
Recruiting - verified March 2015

REgister of Myocardial Infarction Patients Treated by the NOVAra STE-MI Network

Condition:   Acute Myocardial Infarction
Intervention:   Device: Primary PCI
Sponsor:   Azienda Ospedaliero Universitaria Maggiore della Carita
Recruiting - verified March 2015

Novara Registry of Platinum-Chromium Platform Stents

Conditions:   Fracture of Stent of Coronary Artery;   External Causes of Morbidity and Mortality;   Myocardial Infarction;   Coronary Vessel Disorders
Intervention:   Device: coronary angioplasty with PtCr stent implantation
Sponsor:   Azienda Ospedaliero Universitaria Maggiore della Carita
Recruiting - verified March 2015

Complete vs Culprit-only Revascularization to Treat Multi-vessel Disease After Primary PCI for STEMI

Conditions:   Acute Myocardial Infarction;   Coronary Artery Disease;   Percutaneous Coronary Intervention
Intervention:   Procedure: Complete Revascularization Strategy
Sponsor:   Population Health Research Institute
Recruiting - verified March 2015

Does Optical Coherence Tomography Optimise Results of Stenting

Condition:   Acute Coronary Syndromes
Intervention:   Procedure: OCT
Sponsor:   Centre Hospitalier Universitaire de Besancon
Recruiting - verified March 2015

Single Long vs Two Short Overlapping Bioabsorbable Polymer DES

Condition:   Coronary Artery Disease
Intervention:   Device: implantation of a bioabsorbable polymer DES
Sponsor:   Azienda Ospedaliero Universitaria Maggiore della Carita
Recruiting - verified March 2015

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified March 2015

The Impact of Gratitude on Biology and Behavior in Persons With Heart Disease

Conditions:   Myocardial Infarction;   Unstable Angina
Intervention:  
Sponsors:   Massachusetts General Hospital;   University of California, Berkeley
Completed - verified March 2015

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified March 2015

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Other: placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified March 2015

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

Conditions:   Deep Vein Thrombosis;   Venous Thrombosis
Interventions:   Drug: edoxaban tosylate;   Drug: enoxaparin/unfractionated heparin;   Drug: warfarin
Sponsor:   Daiichi Sankyo Inc.
Completed - verified March 2015

HeartTrends Heart Rate Variability (HRV) Algorithm for the Diagnosis of Myocardial Ischemia

Condition:   Ischemic Heart Disease
Intervention:  
Sponsor:   Sheba Medical Center
Completed - verified March 2015

Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI

Condition:   Myocardial Ischemia
Interventions:   Drug: Regadenoson;   Drug: gadofoveset trisodium
Sponsors:   Northwestern University;   Astellas Pharma Global Development, Inc.
Completed - verified March 2015

WEUKBRE5554: IMI PROTECT(Work Package 2): Beta2 Agonists and Acute Myocardial Infarction

Condition:   Asthma
Intervention:   Drug: Inhaled LABA use
Sponsor:   GlaxoSmithKline
Completed - verified March 2015

SmartTouch Catheter in Ablation of Ventricular Tachycardia

Conditions:   Arrhythmias, Cardiac;   Tachycardia, Ventricular;   Myocardial Infarction;   Cardiomyopathies
Intervention:  
Sponsors:   Hospital Universitario Virgen de la Arrixaca;   Biosense Webster, Inc.
Active, not recruiting - verified March 2015

Acute Versus Subacute Angioplasty in Patients With NON-ST-Elevation Myocardial Infarction

Condition:   Myocardial Infarction
Intervention:   Procedure: Group I: Primary PCI
Sponsor:   Aarhus University Hospital Skejby
Recruiting - verified March 2015

Efficacy of the PARI LC Sprint Sp Nebulizer for Acute Asthma Attack in Hospitalized Children Less Than 36 Months of Age

Condition:   Asthma
Interventions:   Device: Standard nebulizer;   Device: PARI LC Sprint Sp nebulizer
Sponsor:   Centre Hospitalier Universitaire de Nīmes
Recruiting - verified March 2015

Evaluating New Radiation Techniques for Cardiovascular Imaging

Condition:   Coronary Disease
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2015

Cardiac Health, Mood, & Neuroimmune Activation

Conditions:   Heart Failure;   Depression
Intervention:  
Sponsor:   University of California, San Diego
Completed - verified March 2015

Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)

Conditions:   Thrombosis;   Coronary Artery Disease
Interventions:   Drug: Prasugrel;   Drug: Clopidogrel
Sponsor:   Indiana University
Recruiting - verified March 2015

Multiple Daily Doses Of Aspirin To Overcome Aspirin Hyporesponsiveness Post Cardiac Bypass Surgery

Condition:   Postoperative; Dysfunction Following Cardiac Surgery
Interventions:   Drug: Aspirin;   Drug: Aspirin;   Drug: Aspirin
Sponsor:   Hamilton Health Sciences Corporation
Completed - verified March 2015

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified March 2015

Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Condition:   Smoking Cessation
Interventions:   Drug: placebo;   Drug: varenicline tartrate;   Drug: bupropion hydrochloride;   Drug: Nicotine Replacement Therapy Patch
Sponsor:   Pfizer
Recruiting - verified March 2015

BIOFLOW-III All-comers Orsiro Safety and Performance Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia
Intervention:  
Sponsor:   Biotronik AG
Active, not recruiting - verified March 2015

Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.

Condition:   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: Losmapimod;   Drug: Placebo
Sponsors:   Cambridge University Hospitals NHS Foundation Trust;   Technology Strategy Board;   GlaxoSmithKline;   Royal Brompton & Harefield NHS Foundation Trust;   University of Cambridge
Completed - verified March 2015

CorMatrix ECM Study: To Identify Inflammatory Markers Following CABG With/Without ECM

Condition:   Coronary Artery Disease
Intervention:   Device: CorMatrix extra cellular matrix (ECM)
Sponsors:   Inova Health Care Services;   CorMatrix Cardiovascular, Inc.
Active, not recruiting - verified March 2015

Prevalence and Long-term Impact of Non-atherosclerotic CAD

Condition:   Myocardial Infarction
Intervention:  
Sponsors:   Cardiology Research UBC;   University of British Columbia
Recruiting - verified March 2015

Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation

Condition:   HIV-1 Infection
Interventions:   Drug: Pravastatin sodium;   Drug: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate;   Drug: Pravastatin sodium
Sponsors:   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Withdrawn - verified March 2015

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified March 2015

Cardiovascular and Torsades de Pointes Monitoring for Pazopanib

Condition:   Carcinoma, Renal Cell
Interventions:   Drug: Pazopanib;   Drug: Other anti-VEGFs
Sponsor:   GlaxoSmithKline
Completed - verified March 2015

The Use of a Restrictive Fluid Regimen With Hypertonic Saline for Patients Undergoing Pancreaticoduodenectomy

Condition:   Pancreaticoduodenectomy
Interventions:   Drug: 3% NaCl Solution;   Drug: Lactated Ringers Solution
Sponsor:   Thomas Jefferson University
Recruiting - verified March 2015

Relation of Diet to Heart Disease Risk Factors in Children

Conditions:   Healthy;   Cardiovascular Disease
Intervention:  
Sponsor:   Children's Hospital & Research Center Oakland
Completed - verified March 2015

Femoral Versus Radial Access for Primary PCI

Condition:   Myocardial Infarction
Intervention:   Procedure: Radial access site vs. Femoral Access site
Sponsor:   Ottawa Heart Institute Research Corporation
Recruiting - verified March 2015

A Study of RoActemra/Actemra (Tocilizumab) in Comparison to Etanercept in Patients With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Condition:   Cardiovascular Disease, Rheumatoid Arthritis
Interventions:   Drug: etanercept;   Drug: tocilizumab [RoActemra/Actemra]
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified March 2015

A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction

Conditions:   Acute Myocardial Infarction;   ST Elevation Myocardial Infarction;   STEMI
Interventions:   Drug: Drug: Placebo;   Drug: Drug: Injectable Thymosin beta 4
Sponsor:   RegeneRx Biopharmaceuticals, Inc.
Suspended - verified November 2012

Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes

Conditions:   Skin Cancer;   Metastatic Melanoma
Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: IL-12 transduced TIL
Sponsor:   National Cancer Institute (NCI)
Terminated - verified March 2015

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: BI 10773 low dose;   Drug: Placebo BI 10773 high dose;   Drug: BI 10773 high dose;   Drug: Placebo BI 10773 low dose;   Drug: Placebo BI 10773 low dose;   Drug: Placebo BI 10773 high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified March 2015

Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)

Condition:   Ankylosing Spondylitis
Intervention:  
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified March 2015

A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via Subcutaneous Injections to Healthy Volunteers

Condition:   Healthy Volunteer
Interventions:   Drug: mipomersen;   Drug: Placebo
Sponsors:   Genzyme, a Sanofi Company;   Isis Pharmaceuticals
Completed - verified March 2015

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified March 2015

Strict or Liberal Insulin Protocol Following Coronary Artery Bypass Graft (CABG) Surgery

Conditions:   Blood Glucose;   Coronary Artery Bypass;   Insulin;   Coronary Disease
Intervention:   Other: LIBERAL
Sponsor:   Inova Health Care Services
Active, not recruiting - verified March 2015

International Active Surveillance Study - Safety of Contraceptives: Role of Estrogens

Condition:   Contraception
Intervention:  
Sponsors:   Center for Epidemiology and Health Research, Germany;   Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Active, not recruiting - verified March 2015

AngelMed for Early Recognition and Treatment of STEMI

Conditions:   Acute Myocardial Infarction (AMI);   Coronary Occlusion;   Acute Coronary Syndrome
Intervention:   Device: AngelMed Guardian System
Sponsors:   Angel Medical Systems;   Symbios Clinical
Active, not recruiting - verified July 2013

A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.

Condition:   Anemia
Interventions:   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta);   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified March 2015

A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers

Conditions:   Myocardial Infarction;   Myocardial Ischemia
Interventions:   Drug: thymosin beta 4;   Other: Placebo
Sponsor:   RegeneRx Biopharmaceuticals, Inc.
Completed - verified March 2015

Natural Killer Cells and Bortezomib to Treat Cancer

Conditions:   Lung or Prostatic Neoplasms;   Colorectal or Kidney Neoplasms;   Pancreatic Neoplasms;   Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive;   Melanoma;   CLL
Intervention:   Drug: NK cells +CliniMACs CD3 and CD56 systems
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2014

Risk Score Alerts for Chest Pain Care

Conditions:   Chest Pain;   Acute Myocardial Infarction
Intervention:   Other: Electronic risk alerts
Sponsors:   Harvard Vanguard Medical Associates;   Brigham and Women's Hospital
Completed - verified March 2015

French Registry of Acute Coronary Syndrome

Condition:   Acute Myocardial Infarction
Intervention:   Other: Blood sample
Sponsors:   Assistance Publique - Hôpitaux de Paris;   French Cardiology Society
Active, not recruiting - verified March 2015

Hepatitis C Treatment and Atherosclerosis

Conditions:   Chronic Hepatitis C;   Atherosclerosis
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified March 2015

Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus

Conditions:   Mixed Connective Tissue Disease (MCTD);   Systemic Lupus Erythematosus (SLE)
Intervention:  
Sponsors:   University of Miami;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified March 2015

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

Condition:   Moderate Risk of CVD
Interventions:   Drug: Aspirin (Acetylsalicylic acid, BAYE4465);   Drug: Placebo
Sponsor:   Bayer
Active, not recruiting - verified March 2015

Safety Study to Assess the Feasibility of Use in Humans of the TAXUS Petal Bifurcation Coronary Stent System

Condition:   Cardiovascular Diseases
Intervention:   Device: Percutaneous Coronary Intervention (PCI) TAXUS Petal
Sponsor:   Boston Scientific Corporation
Completed - verified March 2015

Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis

Condition:   Sarcoidosis
Interventions:   Biological: Autologous hematopoietic stem cell transplantation;   Biological: Allogeneic stem cell transplantation
Sponsor:   Northwestern University
Recruiting - verified March 2015

Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism

Condition:   Rheumatoid Arthritis
Intervention:   Biological: Hematopoietic Stem Cell Transplantation
Sponsor:   Northwestern University
Recruiting - verified March 2015

Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

Condition:   MYOPATHY
Intervention:   Biological: hematopoietic stem cell transplantation
Sponsor:   Northwestern University
Recruiting - verified March 2015

Japan Statin Treatment Against Recurrent Stroke (J-STARS)

Condition:   Ischemic Stroke
Intervention:   Drug: Pravastatin
Sponsors:   Translational Research Informatics Center, Kobe, Hyogo, Japan;   Ministry of Health, Labour and Welfare, Japan;   Hiroshima University
Active, not recruiting - verified March 2015

Get CardioSmart

You're Invited